49 results
Page 2 of 3
F-3/A
n17e 11bt0rua7y2uh5
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
6-K
8ci843e9 mta9d8q
10 Jun 22
Current report (foreign)
6:05am
F-3/A
dtzmoykz6t
20 May 22
Shelf registration (foreign) (amended)
6:54pm
6-K
xjs zl3mgoz1xnla
5 May 22
Current report (foreign)
6:04am
6-K
jla3m4zlpu7d4ri0z2f
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
6-K
EX-99.1
3c1zub w3o9
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
F-3
224ywi 0s4kp3elxb1
15 Apr 22
Shelf registration (foreign)
5:27pm
F-3
EX-1.2
uizkru2a0b3ieq
15 Apr 22
Shelf registration (foreign)
5:27pm
6-K
EX-99.1
tmfd6cc33bsa y5
31 Mar 22
Connect Biopharma Reports Full Year 2021 Financial Results
5:15pm
20-F
8gof7xik
31 Mar 22
Annual report (foreign)
4:33pm
6-K
EX-99.1
ewq0r21xp
5 Jan 22
Current report (foreign)
5:24pm
6-K
EX-99.1
8kjsv3hv68 ff299
19 Nov 21
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis
4:01pm
6-K
EX-99.1
n5b l1f40
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
6-K
EX-99.1
ikb6i
8 Sep 21
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating
8:31am
6-K
EX-99.1
nz7uxqj 0rggqdr
2 Sep 21
Connect Biopharma Announces First Patient Dosed in China Pivotal Trial
4:40pm
6-K
EX-99.3
6aws6a
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
mmh6a621 upmui
27 Aug 21
Current report (foreign)
4:10pm
6-K
EX-99.1
2055nn3ssr1g
3 Jun 21
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
6:04am
6-K
EX-99.1
hi5yjinjftjw
17 May 21
Connect Biopharma Announces First
5:27pm
424B4
3e0bsdweq vbuspo87
19 Mar 21
Prospectus supplement with pricing info
4:49pm